Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel Syndrome With Impaired Intestinal Permeability - Trial NCT06291038
Access comprehensive clinical trial information for NCT06291038 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Rouen and is currently Not yet recruiting. The study focuses on Irritable Bowel Syndrome. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
• Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks
Interventional
dietary supplement
Sponsor & Location
University Hospital, Rouen
Timeline & Enrollment
N/A
Jul 01, 2024
Mar 01, 2029
Primary Outcome
Evaluate the symptomatic effectiveness of glutamine supplementation in patients suffering from IBS-D with increased intestinal permeability
Summary
Irritable bowel syndrome (IBS) affects approximately 5% of the general population and remains
 a daily problem in the practice of clinicians with inconsistent effectiveness of treatments
 while patients' expectations are high.
 
 One of the functional abnormalities described during IBS is increased intestinal
 permeability. This increase in intestinal permeability is primarily present in the diarrheal
 subtype (IBS-D) and can be measured using the lactulose/mannitol test.
 
 Glutamine is a non-essential amino acid which regulates numerous metabolic pathways, and
 which plays a key role in the intestine because it is the preferential substrate of
 enterocytes and immune cells. Ex vivo, glutamine is able to restore the expression of tight
 junction proteins in patients suffering from IBS-D. On the other hand, glutamine
 supplementation is capable of reducing abdominal pain and restoring intestinal permeability
 disorders in a subgroup of patients with intestinal permeability disorder (post-infectious
 IBS-D).
 
 Our working hypothesis would be that all patients suffering from IBS with permeability
 disorder, measured by the lactulose/mannitol test, could benefit from oral glutamine
 supplementation.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06291038
Non-Device Trial